Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of magrolimab combination therapy in head and neck squamous cell carcinoma
2020-005708-20Phase 2Active
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of magrolimab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Safety run-in primary endpoints. Started Oct 2021; status: active.
02
Drugs
magrolimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-005708-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005708-20.